113 related articles for article (PubMed ID: 10965221)
1. Control of catecholamine release and blood pressure with octreotide in a patient with pheochromocytoma: a case report with in vitro studies.
Koriyama N; Kakei M; Yaekura K; Okui H; Yamashita T; Nishimura H; Matsushita S; Tei C
Horm Res; 2000; 53(1):46-50. PubMed ID: 10965221
[TBL] [Abstract][Full Text] [Related]
2. [Hypotension, mental disorders and changes in catecholamine excretion observed during the administration of disulfiram in a case of pheochromocytoma].
Serrano PA; Hava-Kuri I; Chávez-Lara B; Cervantes-Osorio L; Zaldivar HM
Arch Inst Cardiol Mex; 1978; 48(2):437-43. PubMed ID: 666450
[TBL] [Abstract][Full Text] [Related]
3. Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma.
Lamarre-Cliche M; Gimenez-Roqueplo AP; Billaud E; Baudin E; Luton JP; Plouin PF
Clin Endocrinol (Oxf); 2002 Nov; 57(5):629-34. PubMed ID: 12390337
[TBL] [Abstract][Full Text] [Related]
4. Hypertensive crisis induced by metoclopramide in patient with pheochromocytoma.
Abe M; Orita Y; Nakashima Y; Nakamura M
Angiology; 1984 Feb; 35(2):122-8. PubMed ID: 6696287
[TBL] [Abstract][Full Text] [Related]
5. Short-term effects of octreotide on blood pressure and plasma catecholamines and neuropeptide Y levels in patients with phaeochromocytoma: a placebo-controlled trial.
Plouin PF; Bertherat J; Chatellier G; Billaud E; Azizi M; Grouzmann E; Epelbaum J
Clin Endocrinol (Oxf); 1995 Mar; 42(3):289-94. PubMed ID: 7758234
[TBL] [Abstract][Full Text] [Related]
6. Pheochromocytoma and Ca++ channel blocker.
Tomaru A; Oh K; Miura Y; Nakamura H; Yoshikawa M; Horiguchi M
Jpn Heart J; 1986 May; 27(3):429-36. PubMed ID: 3761574
[TBL] [Abstract][Full Text] [Related]
7. Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5-HT4) receptors.
Guillemot J; Compagnon P; Cartier D; Thouennon E; Bastard C; Lihrmann I; Pichon P; Thuillez C; Plouin PF; Bertherat J; Anouar Y; Kuhn JM; Yon L; Lefebvre H
Endocr Relat Cancer; 2009 Mar; 16(1):281-90. PubMed ID: 18948374
[TBL] [Abstract][Full Text] [Related]
8. [A case of adrenal pheochromocytoma with normotention and normal levels of urinary excretion of catecholamines].
Motomura K; Okano J; Sasaki I; Ogihara T; Ishii H; Tanaka A; Ibayashi H; Abe Y; Kuramoto H; Yanase T
Fukuoka Igaku Zasshi; 1994 Sep; 85(9):271-5. PubMed ID: 7959532
[TBL] [Abstract][Full Text] [Related]
9. Increase in blood pressure in pheochromocytoma induced by domperidone and metoclopramide.
Ichikawa S; Ono Z; Arai M; Murata K
Tohoku J Exp Med; 1985 Jun; 146(2):149-52. PubMed ID: 4024091
[TBL] [Abstract][Full Text] [Related]
10. Preoperative management of pheochromocytoma with the calcium-antagonist nifedipine.
Chimori K; Miyazaki S; Nakajima T; Miura K
Clin Ther; 1985; 7(3):372-9. PubMed ID: 3995532
[TBL] [Abstract][Full Text] [Related]
11. Calcium-channel inhibition in pheochromocytoma.
Favre L; Forster A; Fathi M; Vallotton MB
Acta Endocrinol (Copenh); 1986 Nov; 113(3):385-90. PubMed ID: 3788414
[TBL] [Abstract][Full Text] [Related]
12. Pheochromocytoma crisis induced by saralasin. Relation of angiotensin analogue to catecholamine release.
Dunn FG; De Carvalho JG; Kem DC; Higgins JR; Frohlich ED
N Engl J Med; 1976 Sep; 295(11):605-7. PubMed ID: 820996
[No Abstract] [Full Text] [Related]
13. Somatostatin analogue pasireotide (SOM230) inhibits catecholamine secretion in human pheochromocytoma cells.
Streit L; Moog S; Hugel S; Rame M; Tanguy E; Andry V; Schmid HA; Brunaud L; Bihain F; Nominé-Criqui C; Goumon Y; Lacomme S; Lomazzi S; Vix M; Mutter D; Vitale N; Ory S; Gasman S
Cancer Lett; 2022 Jan; 524():232-244. PubMed ID: 34637845
[TBL] [Abstract][Full Text] [Related]
14. Exclusive use of calcium channel blockers in preoperative and intraoperative control of pheochromocytomas: hemodynamics and free catecholamine assays in ten consecutive patients.
Proye C; Thevenin D; Cecat P; Petillot P; Carnaille B; Verin P; Sautier M; Racadot N
Surgery; 1989 Dec; 106(6):1149-54. PubMed ID: 2588118
[TBL] [Abstract][Full Text] [Related]
15. Isradipine, catecholamines, and pheochromocytoma.
Januszewicz W; Wocial B; Chodakowska J; Feltynowski T; Lapiński M
Am J Hypertens; 1991 Nov; 4(11):916-7. PubMed ID: 1838694
[No Abstract] [Full Text] [Related]
16. Catecholamine excretion and circadian blood pressure profile in patients with pheochromocytoma.
Dabrowska E; Lewandowski J; Jedrusik P; Symonides B; Wocial B; Lapinski M; Gaciong Z
Ann N Y Acad Sci; 2006 Aug; 1073():79-85. PubMed ID: 17102074
[TBL] [Abstract][Full Text] [Related]
17. [Catecholamine-induced cardiomyopathy triggered by pheochromocytoma].
Navarro I; Molina M; Civera M; Ascaso JF; Real JT; Carmena R
Endocrinol Nutr; 2011 Apr; 58(4):204-6. PubMed ID: 21393076
[No Abstract] [Full Text] [Related]
18. [2 components of the high-threshold calcium current possessing different sensitivities to omega-conotoxin in the membrane of pheochromocytoma cells].
Pogorelaia NKh; Savchenko AN; Verkhratskiĭ AN; Shuba IaM
Neirofiziologiia; 1990; 22(3):397-400. PubMed ID: 2169035
[TBL] [Abstract][Full Text] [Related]
19. [A reevaluation of the glucagon provocative test for pheochromocytoma--on the in vitro release of catecholamine from the adrenal medulla or pheochromocytoma tissue, and on the effect of intravenous glucagon on urinary catecholamine excretion and blood pressure (author's transl)].
Nakai T; Yamada R; Baba M; Komiya E
Nihon Naibunpi Gakkai Zasshi; 1980 Jun; 56(6):855-67. PubMed ID: 7409274
[TBL] [Abstract][Full Text] [Related]
20. [Alpha-methyl-paratyrosine in the treatment of malignant pheochromocytoma].
Decoulx M; Wemeau JL; Racadot-Leroy N; Grimbert I; Proye C; Plane C
Rev Med Interne; 1987; 8(4):383-8. PubMed ID: 3423477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
